Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …

ADP-ribosylation (ADPRylation) is a post-translational modification of proteins catalyzed by
ADP-ribosyl transferase (ART) enzymes, including nuclear PARPs (eg, PARP1 and PARP2) …

Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant
ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant …

Arginine methylation is an influential post-translational modification occurring on histones,
RNA binding proteins, and many other cellular proteins, affecting their function by altering …

Molecular alterations in cancer genes and associated signaling pathways are used to inform
new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal …

Although the phenomenon of mitotic catastrophe was first described more than 80 years
ago, only recently has this term been used to explain a mechanism of cell death linked to …

EZH2, the catalytic subunit of PRC2, catalyzes histone H3 lysine 27 (H3K27) trimethylation
to induce the agglutination of chromosomes and in turn represses the transcription of the …

Coactivator-associated arginine methyltransferase 1 (CARM1), identified 20 years ago as a
coregulator of transcription, is an enzyme that catalyzes arginine methylation of proteins …

Platinum-based chemotherapies, such as cisplatin, play a large role in cancer treatment.
The development of resistance and treatment toxicity creates substantial barriers to disease …

Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous
carcinoma (HGSOC) representing the most common histological subtype. Approximately …